

88/568761

IA/P20 Rec'd PCT/PTO 21 FEB 2006

1/4

SEQUENCE LISTING

<110> Sumitomo Pharmaceuticals Co., Ltd.  
<120> Method of preventing or treating inflammatory bowel diseases containing as the ingredient CD81 antibodies  
<130> 533734  
<150> JP 2003-304264  
<151> 2003-08-28  
<160> 2  
<170> PatentIn version 3.2  
<210> 1  
<211> 1332  
<212> DNA  
<213> Homo sapiens  
<400> 1  
ccggccgcg ccccgaggc cgccgcgc ccgcgccgc atggagtg aggctgcac 60  
caagtgcatt aagtacctgc tttcgatctt caatttcgtc ttctggctgg ctggaggcgt 120  
gatcctgggt gtggccctgt ggctccgcca tgaccgcag accaccaacc tcctgtatct 180  
ggagctggga gacaagcccc cgcccaacac cttctatgtt ggcatttaca tcctcatcgc 240  
tgtggcgct gtcattgtatgt tcgttggctt cctggctgc tacggggcca tccaggaatc 300  
ccagtgcctg ctggggacgt tttcacctg cctggatcatc ctgtttgcgt gtgagggtggc 360  
cgccggcatc tggggctttt tcaacaagga ccagatcgcc aaggatgtga agcagttcta 420  
tgaccaggcc ctacagcagg ccgtggtgga tggatgacgcc aacaacgcc aggctgtgg 480  
gaagaccttc cacgagacgc ttgactgctg tggctccagc acactgactg ctttgaccac 540  
ctcagtgctc aagaacaatt tggatccctc gggcagcaac atcatcagca acctcttcaa 600  
ggaggactgc caccagaaga tcgatgaccc tttctccggg aagctgtacc tcattggcat 660

tgctgccatc gtggtcgctg tgatcatgtat cttcgagatg atccctgagca tggtgctgtg 720  
ctgtggcatc cgaaacagct ccgtgtactg aggccccgca gctctggcca cagggacctc 780  
tgcagtggccc cctaagtgac ccggacactt ccgagggggc catcaccgccc tgtgtatata 840  
acgtttccgg tattactctg ctacacgttag ccttttact tttggggttt tgtttttgtt 900  
ctgaaccttc ctgttacctt ttcaaggctg acgtcacatg taggtggcgt gtatgagtgg 960  
agacgggcct gggctttggg gactggaggg caggggtcct tctgccctgg ggtcccaggg 1020  
tgctctgcct gctcagccag gccttcctg ggagccactc gcccagagac tcagcttggc 1080  
caactttgggg ggctgtgtcc acccagcccg cccgtcctgt gggctgcaca gtcacccctt 1140  
ttccctccctg ccccggttcg agagccgagt ctgtggcac tctctgcctt catgcacccctg 1200  
tcctttctaa cacgtcgccct tcaactgtaa tcacaacatc ctgactccgt catttaataa 1260  
agaaggaaaca tcagggatgc taaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa 1320  
aaaaaaaaaaa aa 1332

<210> 2  
<211> 236  
<212> PRT  
<213> *Homo sapiens*

<400> 2

Phe Asn Phe Val Phe Trp Leu Ala Gly Gly Val Ile Leu Gly Val Ala  
20 25 30

Leu Trp Leu Arg His Asp Pro Gln Thr Thr Asn Leu Leu Tyr Leu Glu  
35 40 45

Leu Gly Asp Lys Pro Ala Pro Asn Thr Phe Tyr Val Gly Ile Tyr Ile  
50                        55                        60

Leu Ile Ala Val Gly Ala Val Met Met Phe Val Gly Phe Leu Gly Cys  
65                        70                        75                        80

Tyr Gly Ala Ile Gln Glu Ser Gln Cys Leu Leu Gly Thr Phe Phe Thr  
85                        90                        95

Cys Leu Val Ile Leu Phe Ala Cys Glu Val Ala Ala Gly Ile Trp Gly  
100                        105                        110

Phe Val Asn Lys Asp Gln Ile Ala Lys Asp Val Lys Gln Phe Tyr Asp  
115                        120                        125

Gln Ala Leu Gln Gln Ala Val Val Asp Asp Asp Ala Asn Asn Ala Lys  
130                        135                        140

Ala Val Val Lys Thr Phe His Glu Thr Leu Asp Cys Cys Gly Ser Ser  
145                        150                        155                        160

Thr Leu Thr Ala Leu Thr Thr Ser Val Leu Lys Asn Asn Leu Cys Pro  
165                        170                        175

Ser Gly Ser Asn Ile Ile Ser Asn Leu Phe Lys Glu Asp Cys His Gln  
180                        185                        190

Lys Ile Asp Asp Leu Phe Ser Gly Lys Leu Tyr Leu Ile Gly Ile Ala  
195                        200                        205

Ala Ile Val Val Ala Val Ile Met Ile Phe Glu Met Ile Leu Ser Met

4/4

210

215

220

Val Leu Cys Cys Gly Ile Arg Asn Ser Ser Val Tyr  
225                   230                   235